Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
-- Fc-MDNA413 suppresses pro-tumor immune pathways by simultaneously inhibiting IL-4 / IL-13 mediated signaling and proliferation via the Type II IL-4 receptor -- Fc-MDNA413 inhibits in vivo tumor...
-
MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness...
-
Howard Donovan appointed Chief HR Officer, joins executive committee Joerg Hornstein, CFO, will leave to pursue new role Chris Roberts promoted to Vice President, Finance and appointed Interim CFO ...
-
New York, April 08, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Low-Speed Vehicle Market by Type, Power Output, Propulsion, Application and Region - Forecast to...
-
New York, April 08, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Power Grid System Market in Subsea by Component, Application, Depth and Region - Global Forecast to...
-
Pune, India, April 08, 2022 (GLOBE NEWSWIRE) -- Lithium mining market is anticipated to grow at a steady growth rate over the forecast period, owing to an upsurge in demand for the lithium in...
-
Glycotope Presents New Data on Antibodies and Fusion-Proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) Meeting Berlin, Germany, 08 April, 2022 – Glycotope...
-
Korrektionsmeddelelse nr. 12/2022Korrektion til selskabsmeddelelse nr. 11/2022 af d.d. – Korrektion af indkaldelse til ordinær generalforsamling, dagsordenpunkt nr. 6 vedrørende udvidelse af...
-
Correction announcement no. 12/2022 Correction of company announcement no. 11/2022 of today - Correction of notice to convene Annual General Meeting, agenda item no. 6 regarding expansion of the...
-
AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), issued the following shareholder letter today. Dear Fellow...